Results 231 to 240 of about 18,287 (255)
Some of the next articles are maybe not open access.
Journal of Pediatric Urology
Desmopressin is well accepted as first-line medical therapy for enuresis. If ineffective, combination therapy of desmopressin + oxybutynin or desmopressin + imipramine has been used. This study assessed the efficacy of adjunct therapy with either imipramine or oxybutynin in the management of enuresis patients who failed desmopressin treatment.A ...
Spencer Shain +12 more
openaire +2 more sources
Desmopressin is well accepted as first-line medical therapy for enuresis. If ineffective, combination therapy of desmopressin + oxybutynin or desmopressin + imipramine has been used. This study assessed the efficacy of adjunct therapy with either imipramine or oxybutynin in the management of enuresis patients who failed desmopressin treatment.A ...
Spencer Shain +12 more
openaire +2 more sources
2001
Noniatrogenic Cushing’s syndrome is a rare clinical entity that is caused by an inappropriately elevated endogenous cortisol production and results in significant morbidity and mortality in affected patients. Despite its rarity, Cushing’s syndrome represents one of the most challenging diseases in clinical endocrinology because, despite the use of a ...
S. Tsagarakis, N. Thalassinos
openaire +2 more sources
Noniatrogenic Cushing’s syndrome is a rare clinical entity that is caused by an inappropriately elevated endogenous cortisol production and results in significant morbidity and mortality in affected patients. Despite its rarity, Cushing’s syndrome represents one of the most challenging diseases in clinical endocrinology because, despite the use of a ...
S. Tsagarakis, N. Thalassinos
openaire +2 more sources
Desmopressin for the treatment of haemophilia
Haemophilia, 2007Summary. The synthetic vasopressin analogue (1–deamino‐8‐d‐arginine‐vasopressin) increases plasma concentration of factor VIII and von Willebrand factor in normal subjects and patients with mild haemophilia A and von Willebrand disease. Since its first clinical use in 1977, desmopressin has become the treatment of choice for patients with haemophilia ...
openaire +3 more sources
Desmopressin for nocturia in adults
Drug and Therapeutics Bulletin, 2017Desmopressin has been used for many years in the treatment of diabetes insipidus, nocturnal enuresis (involuntary urination while asleep) and nocturia associated with multiple sclerosis (in adults aged up to 65 years); it has also been recommended in certain circumstances for the treatment of nocturia in men and women (previously, an unlicensed use).1 ...
openaire +2 more sources
Desmopressin for Risperidone-Induced Enuresis
Annals of Clinical Psychiatry, 1994AbstractWe present a case report which illustrates the successful use of desmopressin for the treatment of risperidone-induced enuresis.
Lorena J. Wallhausser +2 more
openaire +3 more sources
Intranasal Desmopressin in Mild Hemophilia A
Annals of Internal Medicine, 1985Excerpt To the editor: Recently, de la Fuente and coworkers (1) confirmed that intravenous administration of desmopressin to persons with mild or moderate hemophilia is useful in the management of ...
Ignacio Alberca +3 more
openaire +3 more sources
Desmopressin and bleeding [PDF]
Anaesthesia, 1989 Bidstrup, B. P., Royston, D.
openaire +2 more sources
Desmopressin in Acquired Hemophilia [PDF]
, 1993 Development in non hemophilic patients of an inhibitor to factor VIII (F VIII) is a rare condition which causes severe bleeding problems. These inhibitors are considered as autoantibodies occurring during autoimmune diseases such as lupus erythematosus, rhumatoid polyarthritis, after drug reaction, in the post partum and in 45% of cases in otherwise ...
openaire +1 more source
Desmopressin: A Nontransfusional Hemostatic Agent
Annual Review of Medicine, 1990Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analogue of the antidiuretic hormone L-arginine vasopressin. Because it can raise circulating levels of Factor VIII and of von Willebrand's factor, DDAVP is used for nontransfusional treatment of mild and moderate hemophilia and von Willebrand's disease.
openaire +3 more sources